HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $100 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 86.9%

Neg 0% Neu 86.9% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $100 price target.